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Objectives The authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction
(MI) and stroke in patients with chronic kidney disease (CKD).
Background Patients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase inhibitors (“statins”)
may prevent cardiovascular events in patients with non–dialysis-requiring CKD, adverse drug effects and compet-
ing risks could materially influence net effects and clinical decision-making.
Methods We developed a decision-analytic model of CKD and cardiovascular disease (CVD) to determine the cost-
effectiveness of low-cost generic statins for primary CVD prevention in men and women with hypertension and
mild-to-moderate CKD. Outcomes included MI and stroke rates, discounted quality-adjusted life years (QALYs)
and lifetime costs (2010 USD), and incremental cost-effectiveness ratios.
Results For 65-year-old men with moderate hypertension and mild-to-moderate CKD, statins reduced the combined rate
of MI and stroke, yielded 0.10 QALYs, and increased costs by $1,800 ($18,000 per QALY gained). For patients
with lower baseline cardiovascular risks, health and economic benefits were smaller; for 65-year-old women,
statins yielded 0.06 QALYs and increased costs by $1,900 ($33,400 per QALY gained). Results were sensitive to
rates of rhabdomyolysis and drug costs. Statins are less cost-effective when obtained at average retail prices,
particularly in patients at lower CVD risk.
Conclusions Although statins reduce absolute CVD risk in patients with CKD, the increased risk of rhabdomyolysis, and com-
peting risks associated with progressive CKD, partly offset these gains. Low-cost generic statins appear cost-
effective for primary prevention of CVD in patients with mild-to-moderate CKD and hypertension. (J Am Coll
Cardiol 2013;61:1250–8) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.034Approximately 8% of U.S. adults are believed to have
chronic kidney disease (CKD) (1). Because CKD is an
independent risk factor for cardiovascular disease (CVD),
patients with CKD face increased risks of cardiovascular
(CV) morbidity and mortality (2–4). HMG-CoA reductase
inhibitors (“statins”) are widely used to prevent CVD in the
general population. Although clinical trials failed to dem-
onstrate a benefit from statins in end-stage renal disease
(ESRD) (5,6), subgroup analyses of several large trials
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that they have no relationships relevant to the contents of this paper to disclose.Manuscript received September 19, 2012; revised manuscript received December
17, 2012, accepted December 26, 2012.(7–10) and 3 meta-analyses (11–13) demonstrate that st-
atins reduce the relative risk of myocardial infarction (MI)
and stroke in patients with mild-to-moderate CKD at a
magnitude similar to reduction for non-CKD patients
(7,14). Results from the SHARP (Study of Heart and Renal
Protection) trial also suggest that statins prevent CV events
in patients with advanced, non–dialysis-requiring CKD
(15). Given the high CV risk for patients with non–dialysis-
requiring CKD and the relatively low cost of generic statins,
these drugs have the potential to improve health at an
acceptable cost. Balanced against the potential benefits is
the fact that patients with CKD experience decreased life
expectancy, higher healthcare costs, and reduced quality of
life. Additionally, statin-associated rhabdomyolysis (i.e.,
life-threatening muscle toxicity) is more common in persons
with CKD than in the general population (16).
Although clinical trials support the efficacy of statins for
patients with non–dialysis-requiring CKD, no consensus
recommendations exist for their use in primary prevention.
Several guidelines recommend that CKD be considered a
3
m
C
b
w
a
A
c
y
i
n
e
D
(
d
p
d
B
a
p
l
e
r
o
c
a
r
s
i
m
s
p
t
r
w
t
p
A
N
F
S
s
(
p
i
t
s
s
w
r
(
r
a
W
c
e
c
b
r
A
f
a
r
o
s
e
d
e
v
z
t
e
t
C
o
r
1251JACC Vol. 61, No. 12, 2013 Erickson et al.
March 26, 2013:1250–8 Statins in Chronic Kidney Disease“coronary heart disease risk equivalent” similar to diabetes
when deciding whether to initiate statins (17,18). However,
the Adult Treatment Panel (ATP) III guidelines do not
include CKD as an independent risk factor for CV events
(19). Treating CKD as a coronary heart disease risk equiv-
alent could lead to statin treatment for up to 2 million
additional persons with CKD in the United States (20).
We developed a decision-analytic model to assess the
cost-effectiveness of statins for primary CVD prevention in
non–dialysis requiring CKD. The analysis focuses on the
sizable subset of the CKD population with hypertension,
but with no other traditional CV risk factors, for whom the
ATP III guidelines would not recommend statins.
Methods
Decision-analytic model. We developed a Markov model
of CVD and CKD to evaluate statin therapy for primary CV
prevention in the following cohorts (Online Figs. S1a to S1c):
1. The base case: 65-year-old men and women with mild-
to-moderate CKD and moderate hypertension (systolic
blood pressure [SBP]: 130 to 140 mm Hg on treatment).
2. Additional cohorts of men and women defined by: a) age
at initiation of statins; b) presence (and degree) of hyper-
tension; c) CKD stage; and d) progression of CKD.
The model follows simulated patients over their lifetimes
in 3-month intervals. Individuals can have an acute MI or
stroke, die during or after surviving an MI or stroke, or die
from non-CV causes. Those with prior nonfatal CV events
have further elevated risks of mortality from both repeat CV
events and CVD-associated complications (Online Fig. S1a).
Patients progress through CKD stages 3a (estimated
glomerular filtration rate [eGFR] 45 to 59 ml/min/1.73m2),
b (eGFR: 30 to 44 ml/min/1.73m2), 4 (eGFR: 15 to 29
l/min/1.73m2), and 5 (eGFR 15 ml/min/1.73m2).
osts, quality of life, mortality, and rates of CV events vary
y CKD stages until patients progress to stage 5 CKD, after
hich they experience mortality rates and costs equal to the
verages of similarly aged U.S. patients with ESRD (Online
ppendix: Mortality in ESRD; Online Fig. S1b). Out-
omes included quality-adjusted life years (QALYs), life
ears, direct healthcare costs in 2010 U.S. dollars and
ncremental cost-effectiveness ratios discounted at 3% an-
ually (21). We report costs and incremental cost-
ffectiveness ratios rounded to the nearest $100.
ata. Model inputs were derived from published literature
Table 1). Rates and variability of CKD progression were
erived from large observational cohorts of comparable
atient populations via model calibration (Online Appen-
ix: Modeling CKD Progression, Online Figs. S7 to S11).
aseline probabilities of MI and stroke were derived from
ge- and sex-based Framingham risk scores (Online Ap-
endix: Determining Baseline Cardiovascular Risk). Base-
ine hazards of CV events estimated from the Framingham
quations were multiplied by CKD stage–specific hazard (atios reflecting the increased risk
f CV events independently asso-
iated with CKD stages 3a, 3b,
nd 4 (3,4). All-cause mortality
ates for patients in each CKD
tage were calculated by multiply-
ng CKD stage–specific all-cause
ortality hazards by age- and sex-
pecific mortality in the general
opulation obtained from U.S. life
ables (4,22). For each CKD stage,
ates of noncardiovascular death
ere imputed from all-cause mor-
ality rates by adjusting for com-
eting cardiovascular risks (Online
ppendix: Calibrating Rates of
oncardiovascular Death; Online
igs. S12 to S14).
tatin benefits. Relative risk reductions for MI and stroke in
tages 3a and 3b CKD were obtained from a meta-analysis
11) and were similar to the treatment effect observed in
atients with CKD from the Pravastatin Pooling Project and
n 2 other meta-analyses (9,12,13) (Online Table S5). Al-
hough lacking definitive evidence, evaluation of clinical trials
uggests a trend toward decreased CVD risk reduction from
tatins for patients with stage 4 CKD (11,15). Consequently,
e assumed the CV relative risk reduction equaled that
eported in the SHARP trial for patients with stage 4 CKD
15). Additionally, we assumed that statins do not reduce CV
isks for stage 5 CKD, that is, these patients did not incur
dded costs or receive added health benefits from statins (5,6).
e assumed that all patients, unless statins are contraindi-
ated, would be prescribed statins after experiencing a CV
vent and that published hazards of death and costs of medical
are following CV events reflect the effects of statins. In our
ase case, we assumed statins do not influence the likelihood or
ates of CKD progression (11).
dverse effects of statins. Rates of muscle-related toxicity
rom statins are elevated in patients with CKD (16). We
ssumed patients with CKD on statins experience a 1-time
isk of myalgias upon initiating statin therapy and an
ngoing risk of rhabdomyolysis. Because previous analyses
how that statins for primary prevention are not cost-
ffective if patients experience even minor quality-of-life
ecrements from myalgias (23), we assumed patients who
xperience myalgias discontinue statins. Patients who de-
eloped myalgias incurred a cost for checking muscle en-
yme levels and a 3-month quality-of-life decrement due to
he muscle pain. In the event of rhabdomyolysis, patients
xperience a risk of death from the acute illness, and for
hose surviving, statins were permanently discontinued.
osts and quality of life. We included costs and quality-
f-life decrements for each CKD stage, MI, stroke, and
habdomyolysis, and for patients surviving an MI or stroke
Abbreviations
and Acronyms
ATP  Adult Treatment
Panel
CKD  chronic kidney
disease
CV  cardiovascular
CVD  cardiovascular
disease
eGFR  estimated
glomerular filtration rate
ESRD  end-stage renal
disease
MI  myocardial infarction
QALY  quality-adjusted
life yearTable 1; Online Appendix: Selected Model Assumptions).
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Intervention effects
CV relative risk reduction from statins (stage 3 CKD)* 0.80 0.66 0.85
CV relative risk reduction from statins (stage 4 CKD) 0.83 0.74 1.00
Rate of rhabdomyolysis (per 10,000 person-years) 4.64 0.46 46.40
Probability of death from rhabdomyolysis 0.08 0.07 0.08
Probability of myopathy on statins 0.09 0.02 0.20
Non-CKD natural history parameters
Age-based probability of death in healthy individuals (U.S. life tables) (10%)
Probability of MI and stroke (Framingham model)† (20%)
Probability of death from acute MI 0.07 0.06 0.11
Increased hazard of death after MI, hazard ratio‡ 1.40 1.07 2.04
Probability of death from acute stroke 0.12 0.10 0.19
Increased hazard of death after stroke, hazard ratio‡ 2.30 2.00 2.70
CKD-specific natural history parameters
Increased risk of all-cause mortality (CKD stage 3a), hazard ratio 1.20 1.10 1.30
Increased risk of all-cause mortality (CKD stage 3b), hazard ratio 1.80 1.70 1.90
Increased risk of all-cause mortality (CKD stage 4), hazard ratio 3.20 3.10 3.40
Probability of death from ESRD (see Online Appendix) (20%)
Increased risk of MI and stroke (CKD stage 3a), hazard ratio 1.40 1.30 1.50
Increased risk of MI and stroke (CKD stage 3b), hazard ratio 2.00 1.90 2.10
Increased risk of MI and stroke (CKD stage 4), hazard ratio 2.80 2.60 2.90
Increased hazard of death from acute MI due to CKD (all stages)§ 1.40 1.20 1.60
Increased hazard of death from acute stroke due to CKD (all stages) (38)§ 1.86 1.00 2.00
Rate of CKD progression (ml/min/1.73 m2/year)† 1.36 1.00 2.00
Quality-of-life assumptions, QALY
CKD stage 3a 0.96 0.86 1.00
CKD stage 3b 0.92 0.82 1.00
CKD Stage 4 0.88 0.71 1.00
ESRD 0.70 0.50 0.84
Following MI 0.80 0.50 0.90
Following stroke 0.80 0.40 0.92
While experiencing myalgia 0.80 0.70 0.90
ESRD following a prior CV event 1.00 0.50 1.00
Cost assumptions ($2010)
Annual cost following MI 4,343 50%–200%
Annual cost following stroke 6,060 50%–200%
Annual cost of stage 3a CKD 1,833 50%–200%
Annual cost of stage 3b CKD 4,507 50%–200%
Annual cost of stage 4 CKD 5,844 50%–200%
Acute cost of MI 11,071 50%–200%
First year after MI 7,747 50%–200%
Acute cost of stroke 18,516 50%–200%
First year after stroke 7,770 50%–200%
Cost of rhabdomyolysis 55,794 50%–200%
Monthly cost of statin 4 4 166
Annual laboratory  physician monitoring fees 43
Quality of life assumed to decrease as patients age and differs by sex as observed in the Beaver Dam Study (40). Decreases in health-related quality
of life were applied multiplicatively for patients with more than 1 illness and depended on age and sex. Costs included background medical costs
(see the Online Appendix). End-stage renal disease (ESRD) costs and mortality stratified by age and ESRD duration are derived from national
averages published by USRDS (Online Table S1, Online Fig. S2) (38). Statin costs were not added to these for patients with stage 5 CKD. Patients
experience 0 QALYs for the 2 weeks of hospitalization with rhabdomyolysis. See the Online Appendix for additional references. Asymmetric ranges
appear in some deterministic sensitivity analyses when ranges are obtained from the literature. See the Online Appendix for additional references.
*Applies to CKD stages 3a and 3b, and patients without CKD. †See the Online Appendix (Online Tables S2 to S4; Online Figs. S3 to S4) for more detail
about data sources and model assumptions. ‡Estimates of increased probability of death following MI in CKD versus non-CKD populations are
comparable to the elevated risk of all-cause mortality in CKD. Consequently, baseline all-cause mortality hazard from CKD was substituted to
approximate CKD-specific increased hazard of death following MI and stroke, and was multiplied by post-MI and post-stroke hazards of death to
obtain overall hazard of death in CKD patients following cardiovascular event. §We did not vary hazards across stages due to a lack of data
addressing outcomes from stroke by CKD stage and data demonstrating only mild variation across CKD stage following MI (39,41). See the Online
Appendix for more detail (Online Figs. S5 to S6).
CV  cardiovascular; CKD  chronic kidney disease; MI  myocardial infarction; QALY  quality-adjusted life year.
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March 26, 2013:1250–8 Statins in Chronic Kidney DiseaseIn the base case, statin costs included 40 mg of generic
pravastatin daily available at discount retailers and inte-
grated health systems in addition to laboratory monitoring
and clinical follow-up (24–27).
Alternative assumptions about CKD and model valida-
tion. To understand how CKD progression affects the
ealth benefit and cost-effectiveness of statins, we assessed
utcomes in otherwise similar patient groups with nonprogres-
ive CKD and without CKD. To verify that our assumptions
ccurately describe mortality in patients with CKD, we com-
ared life expectancies produced from each patient group to
.S. life tables, demonstrating stepwise decreases following
dditions of hypertension, nonprogressive CKD, and progres-
ive CKD (Online Tables S6 and S7).
ensitivity analyses. All model inputs were varied in sen-
itivity analyses. The effect of statin costs was tested for a
ange of baseline cardiovascular risks. Probabilistic sensitiv-
ty analysis evaluated how the simultaneous uncertainties
bout model parameters might influence outcomes (Online
ables S8 and S9). We examined scenarios in which statins
ere assumed to slow the rate of CKD progression by up to
9% and scenarios in which statins increased the likelihood
f developing either diabetes or memory loss (28–30).
esults
nitiating statin therapy for patients with mild-to-moderate
stage 3a) CKD, moderate hypertension, and no other CV
Health Benefits, Costs, and Incremental Cost-Effectiveness Ratio FStatin Therapy for Patients With Different Age, S x, and CardiovasTable 2 Health Benefits, Costs, and Incremental Cost-EffectiveStatin Therapy for Patients With Different Age, Sex, an
Starting
Age (yrs)
10-Year Probability
of MI*
Increased
Cost
Gain in QALYs
(Discounted)(%) ($)
Men
50 6 1,700 0.09
55 10 1,800 0.09
60 12 1,800 0.10
65 16 1,800 0.10
70 17 1,500 0.09
75‡ 20 1,300 0.08
80‡ 20 900 0.06
85‡ 20 600 0.04
Women
50 1 1,700 0.03
55 2 1,800 0.04
60 3 1,900 0.05
65 5 1,900 0.06
70 8 1,700 0.06
75 14 1,400 0.06
80 14 1,100 0.05
85 14 700 0.04
For more detailed results see Online Table S10. Because costs are rounded to the nearest $100, in
table suggest. *Determined on the basis of a Framingham risk score (19). †Combined reduction i
recommends that individuals with risk level of 20% or more should be treated with statins. All oth
no other CV risk equivalents.
Abbreviations as in Table 1.isk factors led to a modest improvement in health outcomesfor 50- to 85-year-old men and women (Table 2). For
65-year-old men, statin therapy increased nondiscounted
life expectancy by 50 days (from 11.65 to 11.78 years) and
increased discounted QALYs by 36 days (from 7.21 to 7.31
QALYs). Statins reduced the risk of having at least 1 MI or
stroke over a lifetime (or before progression to ESRD) from
39.8% to 34.7%. Relative benefits were smaller in patients
with lower CV risk. For instance, for 65-year-old women,
statin therapy increased nondiscounted life expectancy by 34
days (from 13.74 to 13.84 years) and increased QALYs by
20 discounted days (from 8.20 to 8.26 QALYs). The
corresponding risk of at least 1 MI or stroke before
development of ESRD was reduced from 24.1% to 20.6%.
Treatment with statins increased total lifetime costs for all
patient groups (Table 2). Combining health benefits and costs,
statin therapy for 65-year-old men with mild-to-moderate
CKD and moderate hypertension cost $18,000 per QALY
gained, and for 65-year-old women cost $33,400 per QALY
gained, assuming the cost of statins at $4 per month (24,25).
Influence of CKD progression. Patients with advanced
CKD and ESRD experience lower health-related quality of
life, higher rates of costly morbidities, and premature
mortality compared with patients without CKD. Although
the increased CV risk in patients with CKD means that
statins provide a larger absolute risk reduction in CV events
compared with patients without CKD, higher “down-
stream” costs and worse health outcomes associated with
Risk Profilesatio From
rdiovascular Risk Profiles
Increased Life Expectancy
(Undiscounted)
Reduced Risk of
MI or Stroke†
Incremental Cost-
Effectiveness Ratio
(Months) (%) ($/QALY)
1.6 4.4 20,500
1.7 4.8 19,600
1.7 5.0 18,900
1.6 5.1 18,000
1.5 5.0 16,900
1.2 4.7 16,300
0.9 4.1 16,100
0.6 3.3 15,400
0.7 2.1 56,800
0.9 2.6 46,200
1.0 3.1 39,200
1.1 3.5 33,400
1.1 3.7 29,300
1.1 3.8 25,000
0.9 3.6 21,300
0.6 3.0 19,800
tal cost-effectiveness ratios may be slightly different than the incremental costs and QALYs in the
ardial infarction (MI) and stroke before development of end-stage renal disease. ‡ATPIII currently
ps of CKD patients in the table would not have statin therapy currently recommended if they hadromcularness
d Ca
cremen
n myoc
er grouprogressive CKD blunted the cost-effectiveness of interven-
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In 65-year-old men and women without CKD and moderate
hypertension, statins cost $10,200 per QALY gained. In
patients of similar age and hypertension severity with mild-to-
moderate, nonprogressive CKD, statins cost $16,400 per
QALY gained, slightly more than in patients without CKD.
With CKD progression, the cost-effectiveness attenuated fur-
ther, reflecting the greater costs and health decrement experi-
enced due to progressive CKD for patients whose CV events
were averted with statins. For a cohort of 65-year-olds with
moderate hypertension, CKD, and the possibility of CKD
progression, statins cost $25,800 per QALY gained (Online
Fig. S15). In other words, statins will allow more patients with
mild-to-moderate CKD to survive free from CV events who
later experience more morbid and costly stages of advanced
CKD and ultimately ESRD.
Age and baseline cardiovascular risk. Older individuals
with CKD have substantially shorter life expectancies,
higher ongoing medical costs, decreased likelihood of sur-
viving long enough to progress to ESRD, and higher CV
risks compared with younger individuals. In net, there was
a trend toward statin use being more cost-effective for older
patients with CKD (Table 2).
Statins were less cost-effective in groups with lower
baseline CV risk. When varying the range of baseline CV
risks (designated by the presence and severity of hyperten-
sion in conjunction with sex and age at statin initiation),
statin therapy cost between $16,100 and $146,700 per
QALY gained (Fig. 1).
Statin prices. When purchased at average retail prices, the
cost-effectiveness of statin therapy compared favorably with
other commonly accepted treatments in patients at higher
CV risks (Fig. 2). If 40 mg of pravastatin is purchased at $47
per month, statin therapy cost between $51,700 and
$87,700 per QALY gained in 50- to 85-year-old men with
mild (SBP: 120 to 130 mm Hg on treatment) or moderate
hypertension and $81,600 to $112,700 per QALY without
hypertension; in women age 70 and older with mild or
moderate hypertension, statin therapy cost between $74,300
and $110,900 per QALY gained. Due to their lower
baseline CV risk, statins were less favorable in younger
women with and without hypertension, where the cost was
$117,700 to $746,700 per QALY gained (Online Tables
S11 and S12; Online Figs. S16 to S18). Despite its greater
potential efficacy (owing to more potent lowering of LDL
cholesterol), brand-name rosuvastatin cost more per QALY
gained, ranging from $80,500 per QALY gained in 65-year-
old men to $390,500 per QALY in 50-year-old women.
Sensitivity analyses. Results were sensitive to the range of
rhabdomyolysis risk in CKD, particularly in younger, lower-
risk groups facing prolonged exposure to statins (Fig. 3). Due
to higher healthcare costs, lower quality of life, and elevated
risk of non-CV mortality in more advanced CKD, statins were
less cost-effective when started in patients with lower GFR,
despite higher CV risks (Online Fig. S24). Although not
definitive, evidence suggests that statins may reduce the rate ofCKD progression (28). If statins were to reduce CKD pro-
gression rates by 19%, they are cost-saving in 65-year old men
and women (Online Fig. S25). When we considered the
possibility of statins causing either diabetes or permanent
memory loss, the cost-effectiveness of statins did not substan-
tially change for CKD patients with higher CV risk (Online
Figs. S26 and S27). However, for CKD patients with lower
CV risks, statin therapy was substantially less cost-effective (or
dominated by a strategy of no statins). In 65-year-old men and
women (who are at higher CV risk), if the long-term risk of
diabetes from statins is 2-fold higher in women and 6-fold
higher in men than described, no statins becomes the preferred
strategy because it yields longer quality-adjusted life expectancy
at a lower cost (Fig. 4).
Probabilistic sensitivity analysis. Considering the simul-
taneous uncertainty in all model parameters, statins cost
$50,000 per QALY gained in over 99% of simulations for
50- and 65-year-old men, and in 94% of simulations for
65-year-old women. In 50-year-old women, statins cost
$50,000 per QALY gained in 38% of simulations, and
cost $100,000 per QALY gained in 90% of simulations
(Online Figs. S28 to S31).
Discussion
Statins for primary prevention of CVD in patients with
moderate hypertension and mild-to-moderate CKD can
increase life expectancy by 0.6 to 1.7 months and prevent
MI or stroke for 2% to 5% of patients before developing
ESRD. If generic statins were obtained at $4 per month
(available from discount retail programs and integrated
health systems) (24,25), they were cost-effective for patients
with a wide range of CV risks, costing$25,803 per QALY
in men with and without hypertension and ranging from
$20,152 to $60,043 per QALY in women with mild or
moderate hypertension, comparing favorably with many
commonly accepted treatments.
Statins are less cost-effective when their prices are higher
and in patients with lower baseline CV risks. At average
retail prices, statin therapy costs between $51,835 and
$97,314 per QALY in men with mild or moderate hyper-
tension and in women above age 70 with moderate hyper-
tension. For patients with lower baseline CV risk (i.e.,
women below age 70 with mild or moderate hypertension,
women of all ages without hypertension, and men below age
60 without hypertension), statin therapy cost between
$100,818 and $746,741 per QALY.
In addition to baseline CV risk and statin price, the
cost-effectiveness of statins was particularly sensitive to
drug-related toxicity. This highlights the importance of
exercising caution when prescribing statins for primary
cardiovascular prevention to patients with CKD. An in-
crease from the baseline incidence of rhabdomyolysis makes
statins substantially less cost-effective when given to
younger patients with lower CV risk. Because lower costs
make statins affordable to larger segments of the population,
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March 26, 2013:1250–8 Statins in Chronic Kidney Diseasepatient education about signs and symptoms of muscle
toxicity, as well as prompt discontinuation of therapy at the
first sign of muscle injury, will be increasingly important.
More knowledge about the relative risks of rhabdomyolysis
from different statins in patients with CKD would be infor-
mative. Additionally, it will be important to verify that long-
term statin risks such as diabetes and memory loss are low.
Our findings suggest that CKD may be different from
traditional CV risk factors when considering statin cost-
effectiveness. Current ATP III guidelines recommend initiating
statin therapy in the general population according to a person’s risk
of future cardiovascular events as determined by a Framingham
CV risk score (31). This recommendation is determined in part on
Figure 1 Statin Cost-Effectiveness: Differing Cardiovascular Ris
(A) Lower cardiovascular risk (women). (B) Higher cardiovascular risk (men). Moderate
mm Hg on treatment; No HTN: SBP: 120 to 130 mm Hg without treatment. *Indicate
III guidelines due to 10-year probability of myocardial infarction (on the basis of traditi
blood pressure.the basis of the observation that the relative reduction in risk ofCVD appears to be independent of the baseline risk (8,32). This
observation has led to past findings that statins are more
cost-effective in higher-risk populations where the absolute risk
reduction is the largest (23,33,34).
Our analysis reaches a different conclusion for adults with
CKD, hypertension, and no other traditional CV risk
factors: Despite an increased risk of MI and stroke in
patients with CKD, statins are not more cost-effective in
patients with CKD than they are in the general population
after considering traditional CV risk factors. This is because
the presence of CKD introduces the following combination
of offsetting health and economic influences: 1) patients
with CKD are at an increased risk of CV disease and related
oups
rtension (HTN): SBP: 130 to 140 mm Hg on treatment; mild HTN: SBP: 120 to 130
nts for whom statins are currently recommended according to Adult Treatment Panel
rdiovascular risk factors)  20%. QALY  quality-adjusted life year; SBP  systolick Gr
hype
s patie
onal camortality, increasing statins’ net benefit; 2) patients with
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Statins in Chronic Kidney Disease March 26, 2013:1250–8CKD are at an increased risk of muscle toxicity, reducing
statins’ net benefit; and 3) CKD progression leads to
increased medical costs, decreased quality of life, increased
non-CV mortality, and apparent ineffectiveness of statins
once patients develop ESRD, reducing statins’ net benefit.
These partly offsetting health and economic influences are
Figure 3 Sensitivity Analysis: Incidence of Rhabdomyolysis
Cost-effectiveness of statins was most sensitive to the risk of rhabdomyolysis in p
in 50-year-old women with moderate hypertension makes statins considerably less
ses. QALY  quality-adjusted life year.
Figure 2 Price Sensitivity Analysis: Cost-Effectiveness at Differ
Treatment effect for pravastatin (relative risk: 0.8) obtained from a meta-analysis
Pravastatin Pooling Project (11). Treatment effect for rosuvastatin obtained from a
program (7). The $4 per month prices obtained from Wal-Mart Retail Prescription P
whereas remaining prices are average retail prices obtained from consumer reportmost pronounced when considering statin therapy in pa-
tients with lower baseline CV risks and when statins are
obtained at higher prices.
Study limitations. First, it is unknown precisely how the
benefits from statin therapy decline as CKD advances.
Although clinical trials demonstrate that statins are effective
s at lower baseline cardiovascular risk; an increase in the rate of rhabdomyolysis
effective. See Online Figures S19 to S23 for additional 1-way sensitivity analy-
tatin Prices
in trials in patients with chronic kidney disease (CKD), weighted heavily by the
ysis of the CKD population from the JUPITER Trial in patients with high C-reactive
Drug List (24) are comparable to those paid by Veterans Affairs facilities (25),
. QALY  quality-adjusted life year.atient
cost-ent S
of stat
n anal
rogram
s (37)
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patients with ESRD have not shown a benefit (5,6).
Because of these disparate observations—and evidence that
CVD may have a different pathophysiologic basis in more
advanced CKD (35)—we assume the treatment effect from
statins diminishes in advanced CKD stages. Although this
assumption reflects current observations, the assumed step-
wise decrease in treatment effect has not been demonstrated
definitively. Second, when patients with CKD progress to
ESRD, medical care becomes substantially more expensive.
By prolonging life in patients with CKD, a part of statins’
incremental cost is due to the high downstream costs of
dialysis. Manns et al. (36) discuss how including down-
stream healthcare costs in economic evaluations of patients
on dialysis are “methodologically correct [but] may mitigate
against the acceptance of interventions that are relatively
inexpensive themselves but which improve patient survival.”
This may pose challenges for policymakers because, as a
society, we currently pay for the high cost of ESRD care. It
is counterintuitive that a strategy aimed at prolonging life
for patients with non–dialysis-requiring CKD would be
subjected to a more stringent criterion; a higher cost-
effectiveness threshold for statins in this population may
therefore be justified. Understanding whether there is a
direct benefit of statins on CKD progression would be
particularly informative in this regard. Finally, the incidence
of diabetes due to statins has been described for the general
population, but is not well described in the CKD popula-
tion. However, in our exploratory analysis, we found statins
to be cost-effective in the base case despite using cost,
Figure 4 Exploratory Analysis: Cost-Effectiveness If Statins Ca
*Estimate of statin-induced diabetes incidence from a meta-analysis. Cost-effectiv
described. If the long-term risk of diabetes from statins is more than 2-fold higher
strategy because it yields longer quality-adjusted life expectancy at a lower cost. Qquality-of-life, and hazard estimates that were weightedtowards making diabetes more severe in its health and
economic ramifications.
Conclusions
Although statins reduce absolute CVD risk in patients with
CKD, increased risk of rhabdomyolysis, and competing risks
associated with progressive CKD, partly offset these gains.
Nevertheless, low-cost generic statins are cost-effective for
primary prevention of CVD in patients with mild-to-moderate
CKD and hypertension. At average retail prices, it could be
argued that statin therapy for patients with CKD should be
reserved for subgroups defined by higher cardiovascular risk
and greater potential to benefit. Statins are only cost-effective
in populations at lower CV risk if they have low risk of rare, but
clinically important, side effects.
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